Dengue vaccine development: challenges and prospects
- PMID: 36098260
- DOI: 10.1097/QCO.0000000000000871
Dengue vaccine development: challenges and prospects
Abstract
Purpose of review: Dengue vaccine development is a high public health priority. To date, no dengue vaccine is in widespread use. Here we review the challenges in dengue development and the latest results for the second-generation dengue vaccines.
Recent findings: The biggest hurdle is the immunological interaction between the four antigenically distinct dengue serotypes. The advantages of second-generation dengue vaccines are the inclusion of nonstructural proteins of the dengue backbone and a more convenient dosing with reduced numbers of doses needed.
Summary: Although dengue-primed individuals can already benefit from vaccination with the first licensed dengue vaccine CYD-TDV, the public health need for the dengue-naive population has not yet been met. The urgent need remains to identify correlates of both protection and enhancement; until such correlates have been identified, all second-generation dengue vaccines still need to go through full phase 3 trials. The 5-year efficacy and safety data for both second-generation dengue vaccines are imminent.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Dengue vaccine development by the year 2020: challenges and prospects.Curr Opin Virol. 2020 Aug;43:71-78. doi: 10.1016/j.coviro.2020.09.004. Epub 2020 Oct 18. Curr Opin Virol. 2020. PMID: 33086187 Free PMC article. Review.
-
[Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].Salud Publica Mex. 2016 Jan-Feb;58(1):71-83. Salud Publica Mex. 2016. PMID: 26879510 Review. Spanish.
-
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Vaccine. 2011. PMID: 21745521 Review.
-
Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.Lancet Infect Dis. 2022 Jun;22(6):901-911. doi: 10.1016/S1473-3099(21)00706-4. Epub 2022 Mar 29. Lancet Infect Dis. 2022. PMID: 35364022 Clinical Trial.
-
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.Lancet Infect Dis. 2021 Apr;21(4):517-528. doi: 10.1016/S1473-3099(20)30767-2. Epub 2020 Nov 16. Lancet Infect Dis. 2021. PMID: 33212067 Clinical Trial.
Cited by
-
Global, regional, and national burden of dengue infection in children and adolescents: an analysis of the Global Burden of Disease Study 2021.EClinicalMedicine. 2024 Nov 19;78:102943. doi: 10.1016/j.eclinm.2024.102943. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39640938 Free PMC article.
-
An economic evaluation of Wolbachia deployments for dengue control in Vietnam.PLoS Negl Trop Dis. 2023 May 30;17(5):e0011356. doi: 10.1371/journal.pntd.0011356. eCollection 2023 May. PLoS Negl Trop Dis. 2023. PMID: 37253037 Free PMC article.
-
Regionality in vector control: effect of fluctuating temperature in the susceptibility of Aedes aegypti (Diptera: Culicidae) larvae to Pyriproxyfen.Parasitol Res. 2023 Dec 11;123(1):23. doi: 10.1007/s00436-023-08065-1. Parasitol Res. 2023. PMID: 38072863
-
30-Year Development of Inactivated Virus Vaccine in China.Pharmaceutics. 2023 Dec 2;15(12):2721. doi: 10.3390/pharmaceutics15122721. Pharmaceutics. 2023. PMID: 38140062 Free PMC article. Review.
-
High seroprevalence of antibodies against arboviruses in postpartum women in Salvador, Brazil.IJID Reg. 2023 Sep 24;9:55-58. doi: 10.1016/j.ijregi.2023.09.004. eCollection 2023 Dec. IJID Reg. 2023. PMID: 37868343 Free PMC article.
References
-
- Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet 2019; 393:350–363.
-
- Yang X, Quam MBM, Zhang T, Sang S. Global burden for dengue and the evolving pattern in the past 30 years. J Travel Med 2021; 28:taab146.
-
- Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21(st) century. Trop Med Health 2011; 39: (4 Suppl): 3–11.
-
- Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study. Lancet Infect Dis 2016; 16:712–723.
-
- Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504–507.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous